NOVOMEDLINK™

This page contains information about Novo Nordisk products.

NovoLog® dosing and delivery

Ease the transition to basal-bolus therapy from basal insulin1

Quick insulin delivery and flexibility with NovoLog® in the pump
By offering your patients NovoLog® in the pump, you're offering more than just rapid-acting insulin therapy. The pump offers convenient delivery that aids in the fast action of NovoLog®.

In fact, after reviewing data that showed NovoLog® was still effective in the pump for up to six days, the FDA gave approval to revise the labeling for this diabetes medication. The label change enables patients to have a more convenient maintenance schedule for insulin pump use.

Label update:

  • NovoLog® can now remain in a pump reservoir for up to 6 days
  • The infusion set and insertion site should be changed at least every 3 days

Blood glucose in pump patients with type 1 diabetes throughout the day2

Blood glucose in NovoLog® pump patients

A 16-week, open-label, randomized, parallel-group study enrolling 146 patients with type 1 diabetes for at least 12 months. Patients were randomized to receive NovoLog®, insulin lispro, or buffered regular insulin as part of continuous subcutaneous insulin infusion (CSII) therapy.2

Buffered regular insulin is no longer manufactured in the United States.

Adapted from Bode et al, 2002.2


Since receiving FDA approval in 2001, NovoLog® has been the trusted insulin analog for pumps and provides the following benefits:

  • Proven effective and safe in patients with either type 1 or type 2 diabetes
  • Remains heat-stable in pumps at normal body temperature (up to 98°F) for use up to 6 days
  • Low incidence of crystal formation in pumps3
  • Low risk of clogs in pump reservoir and distal tubing4
  • First and only rapid-acting insulin for pump use in children with type 1 diabetes

Pediatric pump use for quick insulin delivery with only NovoLog®

  • By study end, nearly 60% of NovoLog® patients reached age-specific A1C goals,† compared with 44% of insulin lispro patients5
  • Mean weight-adjusted daily insulin doses were 0.86 units/kg for NovoLog® and 0.94 units/kg for insulin lispro5
  • Rates of minor, major, and nocturnal hypoglycemic events were similar between treatment groups5

A 16-week, open-label, multicenter, parallel-group study enrolling 298 patients with type 1 diabetes, aged 3 to 18 years. The efficacy and safety of NovoLog® continuous subcutaneous insulin infusion (CSII) therapy was compared with that of insulin lispro. Although patients as young as 3 years were eligible for inclusion, the youngest child included in the study was aged 4 years.5

Patients using external pump infusion therapy should be trained in intensive insulin therapy with multiple injections and in the function of their pump and pump accessories.

† Age-specific A1C goals were defined as <8.5% for subjects aged <6 years and <8.0% for subjects aged 6 to 18 years.5

References:

  1. Hirsch IB, Bergenstal RM, Parkin CG, Wright E Jr, Buse JB. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005;23(2):78-86.
  2. Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care. 2002;25(3):439-444.
  3. Senstius J, Poulsen C, Hvass A. Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps. Diabetes Technol Ther. 2007;9(6):517-521.
  4. Kerr D, Morton J, Whately-Smith C, Everett J, Begley JP. Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J Diabetes Sci Tech. 2008;2(3):450-455.
  5. Weinzimer SA, Ternard C, Howard C, et al; for the Insulin Aspart Pediatric Pump Study Group. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care. 2008;31(2):210-215.

  1. NovoLog® (insulin aspart [rDNA origin] injection) Indications and Usage

    NovoLog® is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

    NovoLog® Important Safety Information

    NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

    NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent. Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulins.

    Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity.

    Needles and NovoLog® FlexPen® must not be shared.

    NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes under the age of two.

    Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog®. Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment.

    All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. It is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy.

    Please see Prescribing InformationPrescribing Information.

FlexPen® and NovoLog® are registered trademarks of Novo Nordisk A/S. NovoMedLink™ is a trademark of Novo Nordisk A/S.